Mayne Pharma Wins $13.27M Court Award After Defeating Cosette’s Legal Claims
Court orders Cosette to pay Mayne Pharma $13.27M in legal costs
The NSW Supreme Court has ordered Cosette Pharmaceuticals, Inc to pay Mayne Pharma Group Limited (ASX: MYX) $13,269,328.04 in legal costs, plus interest, following the company’s success in proceedings against Cosette last year.
The determination, handed down on 22 May 2026, converts a prior adverse costs order into a specific dollar figure. For MYX shareholders, this represents a material potential cash inflow, not simply a legal formality.
When big ASX news breaks, our subscribers know first
How Mayne Pharma got here: the Cosette dispute explained
The Scheme Implementation Deed and its collapse
In February 2025, Mayne Pharma and Cosette Pharmaceuticals signed a Scheme Implementation Deed. Cosette subsequently purportedly terminated the deed, prompting Mayne Pharma to commence legal action to protect its contractual rights.
In June 2025, Mayne Pharma commenced the Termination Proceedings against Cosette in the Supreme Court of New South Wales. The proceedings centred on whether Cosette’s purported termination of the Scheme Implementation Deed was lawful.
October 2025 judgment — Mayne Pharma wins
The Court delivered judgment in favour of Mayne Pharma in October 2025, dismissing all of Cosette’s claims in their entirety. As part of that judgment, the Court made an adverse costs order against Cosette, requiring Cosette to pay Mayne Pharma’s costs of the proceedings “as agreed or assessed.”
Today’s determination is the quantification of that order, translating the costs obligation into a precise dollar amount. The timeline of events is set out below:
- February 2025 — Scheme Implementation Deed signed between Mayne Pharma and Cosette
- Cosette purportedly terminates the deed
- June 2025 — Mayne Pharma commences Termination Proceedings in the NSW Supreme Court
- October 2025 — Court dismisses all of Cosette’s claims; adverse costs order made in Mayne Pharma’s favour
- 22 May 2026 — Court determines Cosette must pay $13,269,328.04 plus interest
What a legal costs award means for investors
In Australian litigation, it is standard practice for the losing party to pay the winning party’s legal costs. This is known as a costs order. The October 2025 judgment was the substantive win on the merits of the dispute; today’s determination is a separate step that quantifies exactly what Cosette must pay to cover Mayne Pharma’s legal expenses.
It is important to note that the interest component of the award has not yet been determined. The Court is expected to make further orders shortly covering the interest amount, the timeframe for payment, and the costs associated with Mayne Pharma’s application for costs. The exact interest figure is not disclosed in this announcement.
The practical significance for investors is that the $13,269,328.04 award, once paid, would flow directly to Mayne Pharma’s balance sheet as a cash recovery. This is subject to Cosette’s compliance and the outcome of any forthcoming orders.
| Component | Status | Amount | Notes |
|---|---|---|---|
| Legal costs award | Determined | $13,269,328.04 | Court order dated 22 May 2026 |
| Interest | Pending | Not yet determined | Court to make further orders shortly |
| Costs of costs application | Pending | Not yet determined | Court to address separately |
| Payment timeframe | Pending | Not yet determined | Court to specify in forthcoming orders |
The next major ASX story will hit our subscribers first
What this means for Mayne Pharma shareholders
The outcome validates Mayne Pharma’s decision to pursue legal action following Cosette’s purported termination of the Scheme Implementation Deed. At each stage of the proceedings, the Court sided with Mayne Pharma, first dismissing all of Cosette’s claims in October 2025 and now quantifying the costs obligation at over $13.27 million.
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on dermatology and women’s health in the United States, with a 40-year track record in developing oral drug delivery systems. A financial recovery of this scale supports the company’s balance sheet as management continues to execute on its core commercial strategy.
Investors should note that further Court orders are expected shortly to give effect to the judgment, including determinations on interest and payment terms. The announcement does not speculate on Cosette’s capacity to pay, and the final cash outcome remains subject to those forthcoming orders.
The recovery of $13.27 million plus interest is a meaningful financial event for an ASX-listed specialty pharmaceutical company. It reinforces the Board’s decision to defend Mayne Pharma’s contractual rights through the courts rather than accept Cosette’s purported termination of the Scheme Implementation Deed.
Don’t Miss the Next Healthcare News Breakthrough
Big News Blast delivers FREE breaking ASX healthcare and pharmaceutical news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.